<DOC>
	<DOCNO>NCT02814591</DOCNO>
	<brief_summary>In study spatially offset Raman spectroscopy ( SORS ) , allow collection Raman spectra turbid medium , apply collect Raman spectrum bone . The principal aim find way use Raman spectroscopy ass bone quality vivo .</brief_summary>
	<brief_title>Development Non-invasive Assessment Human Bone Quality Using Spatially Offset Raman Spectroscopy</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteogenesis Imperfecta</mesh_term>
	<mesh_term>Rickets</mesh_term>
	<mesh_term>Osteomalacia</mesh_term>
	<mesh_term>Osteomyelitis</mesh_term>
	<criteria>INCLUSION CRITERIA Cohort 1 : 40 volunteer , free bone disease : Participants must free bone disease family history OI ; Participants age sex match OP participant may recruit among individual attend RNOH Metabolic Unit DXA scanning , show normal bone density T score &gt; 2.5 ; No history nonaccidental fracture ; No history OA clinical manifestation disease ; No clinical feature OI ; Controls sex age match ( within five year ) disease cohort patient . Children adult require Cohort 2 : 40 patient OI : Patients must clinically diagnosed OI ; Where possible participant identify Royal National Orthopaedic Hospital , Metabolic Unit database ; RNOH diagnosis otherwise confirm Cohort 3 : 40 patient OA : Patients must clinically diagnosed OA ; Participants identify Royal National Orthopaedic Hospital , Metabolic Unit database ; RNOH diagnosis otherwise confirm Cohort 4 : 40 patient OI , receive treatment bisphosphonates : Patients must clinically diagnose OI bisphosphonates prescribed course treatment ; 20 Adults 20 child Where possible participant identify Royal National Orthopaedic Hospital , Metabolic Unit database ; RNOH diagnosis otherwise confirm Where possible measurement acquire prior start treatment 4 follow visit flexible time point allow schedule coincide hospital appointment . The minimum time visit 2 month . Cohort 5 : 2x 30 patient OP ( two treatment group ) : Patients must clinically diagnosed OP ; The first cohort prescribe bisphosphonate antiresorptive treatment ; second anabolic agent . Where treatment cease remains active ( longacting ) , potential participant may include Dr . Keen 's discretion . Where possible participant identify Royal National Orthopaedic Hospital , Metabolic Unit database ; RNOH diagnosis otherwise confirm BMD confirm DXA Where possible measurement acquire prior start treatment 4 follow visit flexible time point allow schedule coincide hospital appointment . Minimum time visit 2 month . Cohort 6 : 1015 participant rickets , 1015 participant osteomalacia Patients must clinically diagnosed rickets/osteomalacia ; Blood test 25hydroxyvitamin D ≤25 nmol/L Once participant treatment measurement make 6 month afterwards Participants rickets osteomalacia group recruit give total 10 complete set data per group Cohort 7 : 5 participant suspect bone infection Participants diagnose RNOH suspect bone infection Participants scan around localised area suspect infection . Measurements may also take away infection side contralateral anatomical location e.g. , infection suspect right knee may also scan right leg leave leg . Participants may 1 2 visit ; latter take place infection clear . This subject fixed time frame . EXCLUSION CRITERIA In general smoker exclude . Exsmokers include give smoke minimum 5 year ago . Cohort 1 : 40 volunteer , free bone disease : A participant history bone disease nonaccidental fracture Clinical feature bone disease Cohort 2 : 40 patient OI ; Cohort 3 : 40 patient OA ; Cohort 6 : 20 patient rickets/osteomalacia • Patients 1 type bone disease Cohorts 4 , 5 6 : receiving treatment • Patients advise stop treatment . If treatment longacting one ( i.e. , remain effective body ) participant may include .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>